|
Malignant Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In Burkitt lymphoma the c-myc gene, the cellular homologue of the viral oncogene v-myc, has been implicated in the aetiology of this human B-cell malignancy.
|
6419124 |
1984 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The identification of a breakpoint to the 3' side of MYC suggests that this recurring translocation is analogous to the variant t(2;8) and t(8;22) translocations observed in the B-cell malignancies.
|
3529089 |
1986 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Deregulation owing to amplification and/or rearrangements of the c-myc gene have been described in a variety of human malignancies.
|
3020069 |
1986 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
These results suggest that translocations t(8;14) involving TcR-alpha and c-myc genes in T-cell malignancies are analogous to variant t(2;8) and t(8;22) translocations observed in Burkitt lymphoma.
|
3466870 |
1986 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Expression of the c-myc gene in human gastrointestinal malignancies.
|
3619899 |
1987 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.
|
3186743 |
1988 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Approximately 30-40% of these tumors exhibit clinical features suggestive of endemic Burkitt lymphoma: they are aggressive malignancies that occur in association with Epstein-Barr virus infection, they arise in the setting of immunosuppression, and they carry t(8;14) translocations without detectable rearrangement of the MYC oncogene.
|
2682665 |
1989 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In certain cases the incidence of aberrant gene expression and genetic alterations of the ras and myc gene families have been shown to be important in the progression of these cancers and may be of use as prognostic indicators.
|
2185684 |
1990 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The expression of the c-myc gene has previously been shown to be elevated and deregulated in the human hepatoma cell line Hep G2 (B. E. Huber and S. S. Thorgeirsson, Cancer Res., 47: 3414-3420, 1987).
|
2154325 |
1990 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
This in vivo rearrangement of the c-myc gene specific to tumor cells may represent one mechanism of activation of a protooncogene during tumorigenesis or tumor progression in human cancer.
|
2334929 |
1990 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Because human lymphoid malignancies frequently contain chromosomal translocations that deregulate the expression of C-MYC and BCL2, our findings could have relevance for attempts to induce terminal differentiation of leukemic cells by in vitro exposure of patients' bone marrow cells to phorbol esters.
|
2011401 |
1991 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A 5'-truncated c-myc gene variant not associated with a risk of cancer.
|
1916760 |
1991 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
B-cell malignancies reveal a number of consistent translocations involving the C-MYC, BCL and IG genes.
|
1954177 |
1991 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
c-myc protein product is a marker of DNA synthesis but not of malignancy in human gastrointestinal tissues and tumours.
|
1933191 |
1991 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
These data indicate that HPV genomes are preferentially integrated near myc genes in invasive genital cancers and support the hypothesis that integration plays a part in tumor progression via an activation of cellular oncogenes.
|
1649348 |
1991 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A c-myc gene variant without exon 1 and with an abnormal methylation pattern inherited in a woman with no evidence of malignancy.
|
1923512 |
1991 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Oncogenic activation of myc genes in human cancer involves deregulated expression of myc proteins with no major structural alterations.
|
1851085 |
1991 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The percentage of c-myc protein-labeled cells in the pituitary adenomas tended to increase with increase with the total scores of clinical malignancy.
|
1575012 |
1992 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In surgical specimens, the immunostain of c-myc protein was not found in normal astrocytes but localized heterogenously in nuclei of reactive astrocytes and glioma cells, and increased in stained cell number in proportion to malignancy.
|
8256584 |
1993 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
It also plays an important role in the progression of human breast cancer. c-myc gene amplification may be important for cancer cell invasion, but perhaps not essential for nodal metastasis.
|
8432027 |
1993 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Twenty five human glial tumours of different grades of malignancy were examined by Southern blotting and polymerase chain reaction (PCR) for alterations (rearrangements, amplification and deletions) in the c-myc gene.
|
8545130 |
1995 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
For example, mutated human proto-myc is postulated to cause Burkitt lymphoma, because avian retroviruses with myc genes cause cancer in birds.
|
8755507 |
1996 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
In contrast, all 6 amplified fragments in NCI-H82 were amplified in several other human cancer cell lines carrying amplified c-myc genes.
|
8707290 |
1996 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The cribriform pattern of cancer had a higher percentage of foci with gain of chromosomes 7, 12, and Y, loss of chromosome 8, and extra copies of c-myc gene than other Gleason Primary Patterns 3 and 4; there was no difference, however, for all paired comparisons of genetic changes between the cribriform pattern of cancer and Gleason Primary Pattern 5 cancer.
|
9388062 |
1997 |